Biosensors launches BioMatrix Flex stent; trial data positive
This article was originally published in Clinica
Biosensors International has launched its BioMatrix Flex drug-eluting stent in Europe, the Middle East, Africa and Asia. The Singapore-based company CE marked BioMatrix Flex for a range of indications, including ST elevated myocardial infarction, acute coronary syndromes and diabetes mellitus, in January (www.clinica.co.uk, 25 January 2010). The device is coated with an abluminal biodegradable polymer and the limus drug Biolimus A9.